difelikefalin (Korsuva) Report issue

Small molecule Approved FDA First in Class Breakthrough Therapy FDA Priority Review FDA
AACT DrugBank PubChem

Active Ingredient History

NOW
  • Now
Difelikefalin, sold under the brand name Korsuva, is an opioid peptide used for the treatment of moderate to severe itch. It acts as a peripherally-restricted, highly selective agonist of the κ-opioid receptor (KOR).   Wikipedia

Chemistry

  • SMILES: CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1
  • InChIKey: FWMNVWWHGCHHJJ-SKKKGAJSSA-N
  • Mol. Mass: 679.86
  • ALogP: 0.83
  • ChEMBL Molecules:
    difelikefalin  
    difelikefalin acetate  
More Chemistry

Pharmacology

Alternative names

cr845 | difelikefalin

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (2)


 

Pruritus (approved 2021)

Renal Insufficiency, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Abdominal Pain (Phase 2/Phase 3)

Acute Pain (Phase 2)

Arthritis (Phase 2)

Dermatitis, Atopic (Phase 3)

Healthy Volunteers (Phase 1)

Joint Diseases (Phase 2)

Musculoskeletal Diseases (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Hip (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pain, Postoperative (Phase 2)

Paresthesia (Phase 2/Phase 3)

Pruritus (Phase 3)

Renal Dialysis (Phase 1)

Renal Insufficiency, Chronic (Phase 3)

Rheumatic Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 28
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue